Compare OVID & MCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVID | MCN |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.5M | 125.2M |
| IPO Year | 2017 | N/A |
| Metric | OVID | MCN |
|---|---|---|
| Price | $2.51 | $5.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $4.20 | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 58.8K |
| Earning Date | 03-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.96% |
| EPS Growth | ★ 3.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,252,000.00 | N/A |
| Revenue This Year | $1,077.56 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1181.27 | N/A |
| 52 Week Low | $0.24 | $5.16 |
| 52 Week High | $2.72 | $6.39 |
| Indicator | OVID | MCN |
|---|---|---|
| Relative Strength Index (RSI) | 76.72 | 35.57 |
| Support Level | $1.31 | $5.65 |
| Resistance Level | N/A | $6.17 |
| Average True Range (ATR) | 0.21 | 0.08 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 82.11 | 23.91 |
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
XAI Madison Equity Premium Income Fund is an investment management company. The Fund invests in an actively managed equity portfolio comprised of individual stocks and covered call options. The Fund's primary investment objective is to provide high level of current income and gains, with a secondary objective of capital appreciation.